Our machine learning analysis revealed a list of chemotherapeutic agents, including doxorubicin, paclitaxel, etoposide, tamoxifen, bortezomib, 5-fluorouracil, methotrexate, imatinib, gemcitabine, and metformin that may target proteins affected by KDAC inhibition under hypoxia in KRAS mutated NSCLC A549 cells. This evidence concerns the gene KRAS and non-small cell lung carcinoma.